Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:01 PM EDT
129.91quote price arrow down-0.31 (-0.24%)
Volume
303,962
52 week range
55.25 - 159.89
Loading...
  • Open131.16
  • Day High131.16
  • Day Low127.83
  • Prev Close130.23
  • 52 Week High159.89
  • 52 Week High Date05/15/23
  • 52 Week Low55.25
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap12.193B
  • Shares Out93.86M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change34.63

KEY STATS

  • Open131.16
  • Day High131.16
  • Day Low127.83
  • Prev Close130.23
  • 52 Week High159.89
  • 52 Week High Date05/15/23
  • 52 Week Low55.25
  • 52 Week Low Date10/31/23
  • Market Cap12.193B
  • Shares Out93.86M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change34.63

RATIOS/PROFITABILITY

  • EPS (TTM)-6.15
  • P/E (TTM)-21.12
  • Fwd P/E (NTM)208.20
  • EBITDA (TTM)-223.427M
  • ROE (TTM)-86.15%
  • Revenue (TTM)1.243B
  • Gross Margin (TTM)87.91%
  • Net Margin (TTM)-43.11%
  • Debt To Equity (MRQ)144.06%

EVENTS

  • Earnings Date04/30/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sarepta Therapeutics Inc

Profile

MORE
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and...
M. Kathleen Behrens Ph.D.
Independent Chairwoman of the Board
Douglas Ingram Esq., J.D.
President, Chief Executive Officer, Director
Ian Estepan
Chief Financial Officer, Executive Vice President
Bilal Arif
Executive Vice President - Strategy and Operations, Chief Technical Operations Officer
Louise Rodino-Klapac Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R and D
Address
215 1st St Ste 415
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
NTRA
Natera Inc
91.11+0.65+0.72%
MEDP
Medpace Holdings Inc
405.88+2.61+0.65%
NBIX
Neurocrine Biosciences Inc
138.10+0.27+0.19%
EXAS
Exact Sciences Corp
70.24+3.36+5.02%
EXEL
Exelixis Inc
23.83-0.03-0.13%